EP4724472A2 - Duale glp-1/gip-, glp-1/gcg-doppel- und glp-1/gip/gcg-dreifachrezeptoragonisten - Google Patents
Duale glp-1/gip-, glp-1/gcg-doppel- und glp-1/gip/gcg-dreifachrezeptoragonistenInfo
- Publication number
- EP4724472A2 EP4724472A2 EP24734139.9A EP24734139A EP4724472A2 EP 4724472 A2 EP4724472 A2 EP 4724472A2 EP 24734139 A EP24734139 A EP 24734139A EP 4724472 A2 EP4724472 A2 EP 4724472A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- moiety
- amino
- absent
- group
- spil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202321039646 | 2023-06-09 | ||
| PCT/IB2024/055620 WO2024252367A2 (en) | 2023-06-09 | 2024-06-07 | Novel glp-1/gip dual and glp-1/gcg dual receptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP4724472A2 true EP4724472A2 (de) | 2026-04-15 |
Family
ID=91585443
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP24734139.9A Pending EP4724472A2 (de) | 2023-06-09 | 2024-06-07 | Duale glp-1/gip-, glp-1/gcg-doppel- und glp-1/gip/gcg-dreifachrezeptoragonisten |
| EP24734138.1A Pending EP4724471A1 (de) | 2023-06-09 | 2024-06-07 | Duale glp-1/gip-, glp-1/gcg-doppel- und glp-1/gip/gcg-dreifachrezeptoragonisten |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP24734138.1A Pending EP4724471A1 (de) | 2023-06-09 | 2024-06-07 | Duale glp-1/gip-, glp-1/gcg-doppel- und glp-1/gip/gcg-dreifachrezeptoragonisten |
Country Status (7)
| Country | Link |
|---|---|
| EP (2) | EP4724472A2 (de) |
| JP (2) | JP2026524764A (de) |
| KR (1) | KR20260022948A (de) |
| CN (2) | CN121285571A (de) |
| AU (1) | AU2024284396A1 (de) |
| MX (1) | MX2025014772A (de) |
| WO (2) | WO2024252367A2 (de) |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE122009000079I2 (de) | 1996-08-30 | 2011-06-16 | Novo Nordisk As Novo Alle | Glp-1 derivate |
| TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
| WO2011075393A2 (en) | 2009-12-18 | 2011-06-23 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| AR080592A1 (es) | 2010-03-26 | 2012-04-18 | Lilly Co Eli | Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso |
| CN103857408B (zh) * | 2011-06-22 | 2017-04-12 | 印第安那大学科技研究公司 | 胰高血糖素/glp‑1受体协同激动剂 |
| JP6184404B2 (ja) | 2011-06-22 | 2017-08-23 | インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション | グルカゴン/glp−1レセプターコアゴニスト |
| CA2872314C (en) | 2012-05-03 | 2021-08-31 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
| AR092873A1 (es) | 2012-09-26 | 2015-05-06 | Cadila Healthcare Ltd | Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon |
| TWI617574B (zh) * | 2012-12-11 | 2018-03-11 | 梅迪繆思有限公司 | 用於治療肥胖之升糖素與glp-1共促效劑 |
| DK3004155T3 (da) | 2013-05-28 | 2022-01-03 | Takeda Pharmaceuticals Co | Peptidforbindelse |
| CA2929459C (en) | 2013-11-06 | 2022-05-03 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
| AU2014345570B2 (en) | 2013-11-06 | 2019-01-24 | Zealand Pharma A/S | Glucagon-GLP-1-GIP triple agonist compounds |
| AR103242A1 (es) | 2015-01-09 | 2017-04-26 | Lilly Co Eli | Compuestos co-agonistas de gip y glp-1 |
| WO2016198624A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists |
| TWI783244B (zh) * | 2015-06-22 | 2022-11-11 | 美商美國禮來大藥廠 | 升糖素及glp-1共激動劑化合物 |
| TWI622596B (zh) | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
| JP6712323B2 (ja) | 2015-12-31 | 2020-06-17 | ハンミ ファーマシューティカル カンパニー リミテッド | グルカゴン、glp−1及びgip受容体のすべてに活性を有する三重活性体 |
| SG10202109721PA (en) | 2016-03-10 | 2021-10-28 | Medimmune Ltd | Glucagon and glp-1 co-agonists for the treatment of obesity |
| KR102505628B1 (ko) * | 2017-09-25 | 2023-03-02 | 머크 샤프 앤드 돔 엘엘씨 | 글루카곤 및 glp-1 수용체의 장기-작용성 공-효능제 |
| CN115304666B (zh) * | 2017-11-24 | 2025-09-19 | 浙江道尔生物科技有限公司 | 一种治疗代谢疾病的胰高血糖素类似物 |
| TWI912614B (zh) * | 2017-12-21 | 2026-01-21 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
| SMT202200352T1 (it) | 2018-04-05 | 2022-09-14 | Sun Pharmaceutical Ind Ltd | Analoghi del glp-1 innovativi |
| AU2019309798A1 (en) | 2018-07-23 | 2021-02-11 | Eli Lilly And Company | Method of using a GIP/GLP1 co-agonist for diabetes |
| ES3068975T3 (en) | 2018-07-23 | 2026-06-03 | Lilly Co Eli | Gip/glp1 co-agonist compounds |
| TW202216746A (zh) | 2020-06-22 | 2022-05-01 | 印度商太陽製藥工業有限公司 | 長效型glp-1/gip雙重促效劑 |
| CN116171164A (zh) | 2020-10-17 | 2023-05-26 | 太阳医药工业有限公司 | Glp-1/gip双重激动剂 |
| TW202313974A (zh) * | 2021-06-08 | 2023-04-01 | 瑞典商阿斯特捷利康公司 | 用於治療肝病之組合療法 |
| CN115975057B (zh) * | 2023-03-16 | 2023-05-16 | 杭州信海医药科技有限公司 | 一种可妥度肽的固相合成方法 |
-
2024
- 2024-06-07 EP EP24734139.9A patent/EP4724472A2/de active Pending
- 2024-06-07 WO PCT/IB2024/055620 patent/WO2024252367A2/en not_active Ceased
- 2024-06-07 JP JP2025571481A patent/JP2026524764A/ja active Pending
- 2024-06-07 KR KR1020257041460A patent/KR20260022948A/ko active Pending
- 2024-06-07 JP JP2025571467A patent/JP2026524763A/ja active Pending
- 2024-06-07 CN CN202480038210.1A patent/CN121285571A/zh active Pending
- 2024-06-07 MX MX2025014772A patent/MX2025014772A/es unknown
- 2024-06-07 AU AU2024284396A patent/AU2024284396A1/en active Pending
- 2024-06-07 WO PCT/IB2024/055618 patent/WO2024252366A1/en not_active Ceased
- 2024-06-07 EP EP24734138.1A patent/EP4724471A1/de active Pending
- 2024-06-07 CN CN202480038209.9A patent/CN121263433A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2025014772A (es) | 2026-01-07 |
| AU2024284396A1 (en) | 2026-01-08 |
| WO2024252366A1 (en) | 2024-12-12 |
| CN121285571A (zh) | 2026-01-06 |
| CN121263433A (zh) | 2026-01-02 |
| WO2024252367A3 (en) | 2025-02-13 |
| JP2026524763A (ja) | 2026-07-24 |
| WO2024252367A2 (en) | 2024-12-12 |
| EP4724471A1 (de) | 2026-04-15 |
| JP2026524764A (ja) | 2026-07-24 |
| KR20260022948A (ko) | 2026-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12622948B2 (en) | GLP-1/GIP dual agonists | |
| RU2559320C2 (ru) | Новые аналоги глюкагона | |
| JP7250814B2 (ja) | 新規glp-1類似体 | |
| EP2124974B1 (de) | Glocagonanaloga mit erhöhter löslichkeit in physiologischen ph-puffern | |
| US20240424063A1 (en) | Long acting glp-1/gip dual agonists | |
| KR20230104118A (ko) | Glp-1 전구약물 및 이의 용도 | |
| SG172170A1 (en) | Glucagon analogues | |
| WO2012167744A1 (en) | Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof | |
| WO2014049610A2 (en) | Peptides as gip, glp-1 and glucagon receptors triple-agonist | |
| WO2007049941A1 (en) | Bioactive substance carrier for in vivo stable delivery tehreof, conjugate containing the same, and method of in vivo stable delivery of the bioactive substance | |
| EP4638481A1 (de) | Triple agonisten des glp1/gip/npy2-rezeptors | |
| WO2024252367A2 (en) | Novel glp-1/gip dual and glp-1/gcg dual receptor agonists | |
| CN116589536B (zh) | 一类长效glp-1/gip受体双重激动剂及其应用 | |
| CN115873096B (zh) | 一种胰高血糖素糖肽-1和胰高血糖素受体双重激动多肽及其应用 | |
| CA2606894A1 (en) | Novel compounds as glp-i agonists | |
| CN115232200B (zh) | 长效化Exendin-4类似物及其应用 | |
| CN116514952B (zh) | 一类glp-1类似物及其应用 | |
| EA053025B1 (ru) | Двойные агонисты glp-1/gip |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20251222 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR |